Peptides
KPV
A three-amino-acid research peptide with cell and mouse-colitis findings, without established human bowel-disease benefit in these sources.
Cell and mouse experiments
Also known as: Lys-Pro-Val
Practical use
Reviewed practical notes
- Identify the peptide
- KPV is a short fragment, not the complete alpha-MSH hormone.
- Keep the model visible
- Mouse colitis and cultured cells do not demonstrate clinical remission.
- Avoid symptom-based extrapolation
- The experiments do not establish a treatment for undiagnosed digestive symptoms.
Overview
KPV stands for lysine-proline-valine, a short fragment associated with alpha-melanocyte-stimulating hormone. It has been investigated for effects on inflammatory signaling and intestinal peptide transport. A fragment has its own pharmacology; results from the full hormone are not automatically KPV results.
Risks and limitations
These experiments do not establish human adverse-effect rates, drug interactions or long-term safety. Suppressing inflammatory signals under laboratory conditions also does not establish that a product is effective for every cause of abdominal symptoms.
How to read this
Chemically induced mouse colitis is useful for testing hypotheses, but differs from the varied causes and long course of human inflammatory bowel disease. The reviewed sources do not support replacing established diagnostic evaluation or prescribed treatment with KPV.
Research explained
Peptide transport and inflammatory signaling
Who was studied
Human-derived intestinal and immune cell lines, together with experimental mouse-colitis models.
What was found
Researchers found transport through PepT1 and reductions in selected inflammatory signaling and cytokine responses; mouse inflammatory outcomes also improved.
What it cannot establish
Cultured human cells are not treated patients. Transporter activity and mouse outcomes do not establish human remission or mucosal healing.
Read the original studyTwo mouse-colitis models
Who was studied
Mice with chemically induced or immune-cell-transfer colitis, including a model with impaired melanocortin-1 receptor function.
What was found
KPV was associated with improved recovery and reduced tissue inflammation under the tested conditions.
What it cannot establish
The results suggest that some effects need not depend on intact melanocortin-1 signaling. They do not establish a complete mechanism, clinical efficacy or a human safety profile.
Read the original studyThe disease model limits the claim
Reduced inflammatory infiltrates in a mouse colon are encouraging preclinical findings. Demonstrating a useful treatment in people requires patient outcomes, an appropriate comparator and systematic harms assessment.
Supporting sourceSources
2008 PepT1 and inflammatory-signaling study
Sources checked 2026-10-01.
General education; not a personal treatment plan.